ID: MRFR/HC/6899-HCR | 100 Pages | Author: Kinjoll Dey | June 2023
Non-Invasive Prenatal Testing (NIPT) Market is expected to cross USD 11.16 Billion at a CAGR of 13.16 % by 2030.
$11.16 Billion
13.16%
North America
2022-2030
The Non-Invasive Prenatal Testing Market is expected to reach USD 3.99 Billion by 2030 at 12.90% CAGR during the forecast period 2022-2030.
Non-Invasive Prenatal Testing (NIPT) Market Synopsis
NIPT is the testing procedure done during the pregnancy period to monitor the fetal growth and related diagnosis. Annually it is predicted that around 21 million girls aged 15 to 19 years give birth in developing regions around the globe.
Thus, it is among the reasons why NIPT is needed for safe delivery of the baby.
The birth rate is expected to increase during the forecast period.
Market Influencer
Rising cases of premature pregnancy in developing and underdeveloped countries.
Non-Invasive Prenatal Testing (NIPT) Market Drivers
Non-Invasive Prenatal Testing (NIPT) Market Restraints
Non-Invasive Prenatal Testing (NIPT) Market Segmentation
By Product Type
The Non-Invasive Prenatal Testing (NIPT) Market based on product type is broadly segmented into devices, consumables, and others.
By Techniques
The non-Invasive prenatal testing (NIPT) market based on technique is segmented into biochemical screening tests and ultrasound detection.
By Application
By End-User
Non-Invasive Prenatal Testing (NIPT) Market By Region
Non-Invasive Prenatal Testing (NIPT) Market Key Players
Report Attribute/Metric | Details |
---|---|
Market Size | 2030: USD 11.16 Billion |
CAGR | 13.16% (2022-2030) |
Base Year | 2021 |
Forecast Period | 2022-2030 |
Historical Data | 2020 |
Forecast Units | Value (USD Billion) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Product Type, Techniques, Application, End User |
Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors | Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), General Electric Company [GE Healthcare] (US), Perkinelmer, Inc. (US), Agilent Technologies, Inc. (US), Beijing Genomics Institute (China), Hoffman-La Roche Ltd. (Switzerland), Tarsa Therapeutics, Inc. (US), PhytoHealth Corporation (Taiwan), Laboratory Corporation of America Holdings (US), Natera, Inc. (US), Yourgene Health (UK), Centogene Holding AG [CENTOGENE AG ] (Germany) |
Key Market Opportunities | New product launches and R&D Amongst major key Players |
Key Market Drivers | Growing global population. Adoption of unhealthy lifestyle habits during pregnancy. Rising awareness of non-invasive prenatal testing. |
The global non-invasive prenatal testing (NIPT) market is projected to reach a valuation of USD 3.99 Billion by 2030.
The global non-invasive prenatal testing (NIPT) market is projected to grow at approximately 12.90% CAGR during forecast period (2022-2030).
Thermo Fisher Scientific, Inc. (US), Illumina, Inc. (US), General Electric Company [GE Healthcare] (US), Agilent Technologies, Inc. (US), Perkinelmer, Inc. (US), Beijing Genomics Institute (China), Tarsa Therapeutics, Inc. (US), Hoffman-La Roche Ltd. (Switzerland), PhytoHealth Corporation (Taiwan), Natera, Inc. (US), Laboratory Corporation of America Holdings (US), Centogene Holding AG (Germany), and Yourgene Health (UK), are some of the major players operating in the non-invasive prenatal testing (NIPT) market.
North America holds the largest share in the global non-invasive prenatal testing (NIPT) market, followed by Europe and the Asia Pacific, respectively.
Adoption of unhealthy lifestyle habits during pregnancy.
Key Questions Answered
Why Choose Market Research Future?